FIELD: biotechnology.
SUBSTANCE: in particular, the present invention is based on experimental data, according to which the synthesis of type I collagen in tenocytes is less susceptible to the effect of miR-29 compared to collagen of the third type, which enables to shift the ratio between collagen subtypes in favour of increasing collagen content of type 1 and thereby preventing a decrease in the biomechanical properties of the tendon in the healing process.
EFFECT: present invention relates to biotechnology, particularly the use of microRNA 29 and its precursors, as well as mimetics for modulating a tendon injury and biomechanical properties of the tendon.
28 cl, 17 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF microRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSTICS AND TREATMENT | 2014 |
|
RU2644247C2 |
| CLOSED-END LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER | 2017 |
|
RU2752882C2 |
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| VERSIONS OF RECOMBINANT AAV AND USE THEREOF | 2015 |
|
RU2738421C2 |
| CHIMERIC ANTIBODIES FOR TREATMENT OF DISEASES CHARACTERIZED BY AMYLOIDE DEPOSITION | 2018 |
|
RU2746325C1 |
| GENE THERAPY OF OPHTHALMIC DISORDERS | 2016 |
|
RU2762747C2 |
| METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS AND DISEASES RELATED TO RDH12 | 2017 |
|
RU2764920C2 |
| BIOMARKERS OF TRAUMATIC BRAIN INJURY | 2017 |
|
RU2771757C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| MIR-29 MIMETICS AND WAYS OF USE THEREOF | 2015 |
|
RU2712511C2 |
